We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-2.94%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$339M
(-18%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-18.81%
Top 10 Holdings %
Top 10 Hldgs %
41.55%
Holding
80
New
12
Increased
20
Reduced
21
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$51M |
| 2 |
Natera
NTRA
|
+$41.9M |
| 3 |
Becton Dickinson
BDX
|
+$37.3M |
| 4 |
Cytokinetics
CYTK
|
+$37M |
| 5 |
Abbott
ABT
|
+$35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$158M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$85.6M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$49.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$47.9M |
| 5 |
Tenet Healthcare
THC
|
+$40.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.96% |
| 2 | Consumer Discretionary | 1.59% |
| 3 | Financials | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RVNC
26
DELISTED
Revance Therapeutics, Inc.
RVNC
| $27.8M | 1.85% |
1,423,425
-26,410
| -2% | -$401K |
|
27
Amgen
AMGN
$222B
| $26.3M | 1.76% |
108,890
+46,400
| +74% | +$10.7M |
|
|
28
Tenet Healthcare
THC
$21.1B
| $24.4M | 1.63% |
283,730
-498,450
| -64% | -$40.9M |
|
|
CCXI
29
DELISTED
ChemoCentryx, Inc.
CCXI
| $24M | 1.6% |
956,740
+716,210
| +298% | +$20.1M |
|
30
Petco
WOOF
$794M
| $23.8M | 1.59% |
1,215,000
-1,514,450
| -55% | -$28.3M |
|
31
Henry Schein
HSIC
$9.82B
| $22.3M | 1.48% |
255,230
+127,620
| +100% | +$10.4M |
|
32
Syndax Pharmaceuticals
SNDX
$1.82B
| $20.5M | 1.37% |
1,180,500
+22,940
| +2% | +$386K |
|
33
Cardinal Health
CAH
$55.4B
| $18M | 1.2% |
+317,280
| New | +$17M |
|
|
RACB
34
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $12.9M | 0.86% |
1,324,800
| – | – |
|
35
Pfizer
PFE
$153B
| $12.6M | 0.84% |
242,880
-96,230
| -28% | -$4.99M |
|
36
HCA Healthcare
HCA
$89.5B
| $12.3M | 0.82% |
48,890
-35,380
| -42% | -$8.88M |
|
37
Stryker
SYK
$130B
| $11.7M | 0.78% |
43,760
-115,180
| -72% | -$29.8M |
|
|
AFMD
38
DELISTED
Affimed
AFMD
| $7.53M | 0.5% |
172,193
| – | – |
|
39
Quanterix
QTRX
$190M
| $7.2M | 0.48% |
246,540
+112,200
| +84% | +$3.43M |
|
40
Maravai LifeSciences
MRVI
$919M
| $7.05M | 0.47% |
+200,000
| New | +$6.7M |
|
41
Regeneron Pharmaceuticals
REGN
$80.8B
| $6.68M | 0.45% |
9,570
-18,750
| -66% | -$11.9M |
|
|
IMGN
42
DELISTED
Immunogen Inc
IMGN
| $6.24M | 0.42% |
1,310,340
| – | – |
|
43
Hyperfine
HYPR
$94.8M
| $6.2M | 0.41% |
1,750,000
+1,058,350
| +153% | +$4.37M |
|
|
RAPT
44
DELISTED
RAPT Therapeutics
RAPT
| $5.81M | 0.39% |
33,019
+10,344
| +46% | +$1.95M |
|
|
CANO
45
DELISTED
Cano Health, Inc.
CANO
| $4.52M | 0.3% |
7,120
-8,747
| -55% | -$5.51M |
|
46
BioCryst Pharmaceuticals
BCRX
$2.4B
| $3.71M | 0.25% |
228,450
-2,148,680
| -90% | -$34.5M |
|
47
Alkermes
ALKS
$8.25B
| $3.7M | 0.25% |
+140,630
| New | +$3.48M |
|
48
iShares Biotechnology ETF
IBB
$9.77B
| $3.68M | 0.25% |
+28,220
| New | +$3.68M |
|
49
Stereotaxis
STXS
$141M
| $3.07M | 0.2% |
821,850
+165,310
| +25% | +$780K |
|
|
MRUS
50
DELISTED
Merus
MRUS
| $2.96M | 0.2% |
111,760
| – | – |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2022 Portfolio in Review
As of Q1 2022, HealthCor Management held 80 positions worth $1.5B, down 18% from $1.84B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
HealthCor Management withdrew a net $282M in Q1 2022, closing 16 positions and reducing 21 holdings. Its most notable exit was Medtronic, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, HealthCor Management opened a new position in Becton Dickinson worth $37.6M.
- HealthCor Management's largest Q1 2022 buy was Becton Dickinson: 144,997 shares worth $37.6M.
- HealthCor Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $51M increase.
- HealthCor Management's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $85.6M.
- HealthCor Management fully exited Medtronic in Q1 2022, selling an estimated $158M.
- HealthCor Management's ten largest holdings make up 42% of its $1.5B portfolio in Q1 2022.
- HealthCor Management opened 12 new positions and closed 16 in Q1 2022.
- HealthCor Management's portfolio value fell 18% quarter-over-quarter to $1.5B.
Based on HealthCor Management's 13F filing for Q1 2022, filed 16 May 2022.